Invion Ltd has released a press release.
EQR Progresses Regional Tungsten Hub Strategy
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Invion
- Loyalty Option Entitlement Offer
- Encouraging SRC Findings on Ph I/II Skin Cancer Trial
- Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
- Appendix 4C and Quarterly Activities Report - March 2025
- Share Purchase Agreement Termination and Tranche Repayment
Later from Invion
- Underwritten Loyalty Option Entitlement Offer Prospectus
- Security Class Suspension from Quotation
- Security Class Reinstatement to Quotation
- Appendix 4C and Quarterly Activities Report - June 2025
- Orphan Drug Designation Granted by U.S. FDA For Anal Cancer
Follow Invion into a list and get an email when it puts out news.
Follow Invion